Answers are grounded in this paper and cite their sources.
Absence epilepsy, a subtype of idiopathic generalized epilepsy, accounts for 10-15% of pediatric cases and, despite its benign reputation, can persist into adulthood with associated cognitive deficits. 1,2First-line treatments such as ethosuximide, valproic acid, and lamotrigine are effective in many cases, but drug resistance and adverse effects remain challenges. 3This underscores the need for alternative therapies that also address underlying epileptogenic mechanisms.The brain relies heavily on glucose metabolism for neuronal function, consuming nearly 20% of the body's total glucose. 4Glucose uptake is mediated by facilitated glucose transporters (GLUTs) and sodium-glucose cotransporters (SGLTs). [5][6]6][7] Although SGLTs were initially identified in peripheral organs, recent findings confirm their presence in brain regions such as the hippocampus, cortex, and hypothalamus. 8While SGLT2 is minimally expressed in the healthy brain tissue, it may be upregulated under pathological conditions, including epilepsy. 9Inhibition of SGLTs can limit intracellular glucose availability, potentially triggering energy imbalance and increased seizure susceptibility.Conversely, selective SGLT2 inhibition has shown neuroprotective effects in some models, possibly via enhanced ketogenesis, redox stabilization, and anti-inflammatory pathways. [10][11]1][12] Dapagliflozin, a selective SGLT2 inhibitor used for type 2 diabetes, has demonstrated both pro-and anti-epileptic effects in preclinical models.For example, phlorizin worsened seizures in the pilocarpine model, 13 while dapagliflozin reduced seizure activity and neuroinflammation in pentylenetetrazol (PTZ) and pilocarpine models. 9,14star Albino Glaxo from Rijswijk (WAG/Rij) rats are a well-established genetic model of absence epilepsy, developing spontaneous spike-and-wave discharges (SWDs) akin to human absence seizures after three months of age. 15,16This model provides a robust platform for evaluating anti-epileptic interventions targeting idiopathic generalized epilepsy.In this study, we evaluated the acute, dose-dependent effects of dapagliflozin on absence seizures in WAG/Rij rats using in vivo electrocorticography (ECoG) recordings.To our knowledge, this is the first report examining SGLT2 inhibition in this genetic model, aiming to clarify the dualistic impact of dapagliflozin on seizure modulation and to explore SGLT2 as a metabolic target in epilepsy.
No takes yet. Share an insight, caveat, or question.
Hatice Aygün (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: